FibroBiologics, Inc. Common Stock (FBLG) Stock Score, Valuation & Financial Research

FibroBiologics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for FBLG

FibroBiologics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 1.13. These figures are a research snapshot, not a buy or sell recommendation.

What FibroBiologics, Inc. Common Stock does

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

FibroBiologics is a clinical-stage biotechnology company that focuses on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company generates no revenue from product sales as it is currently in the research and development phase, relying on capital raises and financing activities to fund its operations.

Products and services

  • The company is developing fibroblast-based cell therapies for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. Its primary product candidates include CYWC628, CYPS317, CYMS101, and CybroCell.

Customer types

Healthcare providers and patients suffering from chronic diseases.

Suppliers, materials and equipment

  • Contract Development and Manufacturing Organizations (CDMOs) — The company partners with unnamed CDMOs for clinical and commercial manufacturing services. Source

Business strengths to evaluate

  • Extensive intellectual property portfolio with over 270 issued and pending patents Source

Business risks and research considerations

  • History of operating losses and expectation of continued losses Source
  • Material weakness in internal control over financial reporting Source

Sources: Company research source · Extensive intellectual property portfolio with over 270 issued and pending patents

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

FBLG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.13
Market capitalization:
2.37M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.14M
Free cash flow:
USD -16.66M
Cash:
USD 3.52M
Total debt:
USD 1.46M
EPS:
USD -6.00

What stands out

  • Free cash flow is USD -16.66M, negative for the stored period.
  • The balance sheet shows USD 3.52M of cash versus USD 1.46M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.05M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for FBLG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can FBLG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is FBLG likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for FBLG to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of FBLG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research FBLG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.